A nationwide survey of hepatitis C services provided by drug treatment programs

Shiela M. Strauss; Gregory P. Falkin; Zdravko Vassilev; Don C. Des Jarlais; Janetta Astone

doi:10.1016/S0740-5472(01)00213-6

A nationwide survey of hepatitis C services provided by drug treatment programs

Shiela M. Strauss, Gregory P. Falkin, Zdravko Vassilev, Don C. Des Jarlais, Janetta Astone

Research output: Contribution to journal › Article › peer-review

Abstract

Drug treatment programs are a site of opportunity for the delivery of primary and secondary hepatitis C (HCV) prevention services to drug users, a population at great risk for contracting and transmitting the virus. Using data collected from a random nationwide sample (N = 439) of drug treatment programs in the United States, this study examines the extent to which various types of HCV services are provided to their patients. Findings indicate that the majority of drug treatment programs educate at least some of their patients about HCV, and provide some type of support for patients who are infected with the virus. Only 29 of the programs in the sample test all of their patients for HCV, however, and 99 programs test none of them. For the most part, residential treatment programs offer more HCV related services than outpatient drug-free programs.

Original language	English (US)
Pages (from-to)	55-62
Number of pages	8
Journal	Journal of Substance Abuse Treatment
Volume	22
Issue number	2
DOIs	https://doi.org/10.1016/S0740-5472(01)00213-6
State	Published - 2002

Keywords

Disease prevention
Drug treatment programs
HCV services
Telephone survey
Treatment modality

ASJC Scopus subject areas

Phychiatric Mental Health
Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Access to Document

10.1016/S0740-5472(01)00213-6

Cite this

@article{6e5ddcd1c2ed4744a7c419b51ab02603,

title = "A nationwide survey of hepatitis C services provided by drug treatment programs",

abstract = "Drug treatment programs are a site of opportunity for the delivery of primary and secondary hepatitis C (HCV) prevention services to drug users, a population at great risk for contracting and transmitting the virus. Using data collected from a random nationwide sample (N = 439) of drug treatment programs in the United States, this study examines the extent to which various types of HCV services are provided to their patients. Findings indicate that the majority of drug treatment programs educate at least some of their patients about HCV, and provide some type of support for patients who are infected with the virus. Only 29 of the programs in the sample test all of their patients for HCV, however, and 99 programs test none of them. For the most part, residential treatment programs offer more HCV related services than outpatient drug-free programs.",

keywords = "Disease prevention, Drug treatment programs, HCV services, Telephone survey, Treatment modality",

author = "Strauss, {Shiela M.} and Falkin, {Gregory P.} and Zdravko Vassilev and {Des Jarlais}, {Don C.} and Janetta Astone",

note = "Funding Information: Funding for this study was provided by the National Institute on Drug Abuse (grant no. 1-R01 DA13409). Points of view do not represent the official positions of the Federal government, NIDA, or NDRI. We especially wish to thank Deborah Trunzo, of the Office of Applied Studies, SAMHSA, for her kind assistance in arranging for the project{\textquoteright}s use of the I-SATS database. We also thank Sarah Krassenbaum, Kim Sanders, and Kristine Ziek, the project interviewers, for their consistent efforts to ensure the best possible rate of treatment program participation in the research, and whose high standards are reflected in the excellent quality of the data. An earlier version of this paper was presented at the Sixty-third Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ, June 2001.",

year = "2002",

doi = "10.1016/S0740-5472(01)00213-6",

language = "English (US)",

volume = "22",

pages = "55--62",

journal = "Journal of Substance Abuse Treatment",

issn = "0740-5472",

publisher = "Elsevier Inc.",

number = "2",

}

TY - JOUR

T1 - A nationwide survey of hepatitis C services provided by drug treatment programs

AU - Strauss, Shiela M.

AU - Falkin, Gregory P.

AU - Vassilev, Zdravko

AU - Des Jarlais, Don C.

AU - Astone, Janetta

N1 - Funding Information: Funding for this study was provided by the National Institute on Drug Abuse (grant no. 1-R01 DA13409). Points of view do not represent the official positions of the Federal government, NIDA, or NDRI. We especially wish to thank Deborah Trunzo, of the Office of Applied Studies, SAMHSA, for her kind assistance in arranging for the project’s use of the I-SATS database. We also thank Sarah Krassenbaum, Kim Sanders, and Kristine Ziek, the project interviewers, for their consistent efforts to ensure the best possible rate of treatment program participation in the research, and whose high standards are reflected in the excellent quality of the data. An earlier version of this paper was presented at the Sixty-third Annual Scientific Meeting of the College on Problems of Drug Dependence, Scottsdale, AZ, June 2001.

PY - 2002

Y1 - 2002

N2 - Drug treatment programs are a site of opportunity for the delivery of primary and secondary hepatitis C (HCV) prevention services to drug users, a population at great risk for contracting and transmitting the virus. Using data collected from a random nationwide sample (N = 439) of drug treatment programs in the United States, this study examines the extent to which various types of HCV services are provided to their patients. Findings indicate that the majority of drug treatment programs educate at least some of their patients about HCV, and provide some type of support for patients who are infected with the virus. Only 29 of the programs in the sample test all of their patients for HCV, however, and 99 programs test none of them. For the most part, residential treatment programs offer more HCV related services than outpatient drug-free programs.

AB - Drug treatment programs are a site of opportunity for the delivery of primary and secondary hepatitis C (HCV) prevention services to drug users, a population at great risk for contracting and transmitting the virus. Using data collected from a random nationwide sample (N = 439) of drug treatment programs in the United States, this study examines the extent to which various types of HCV services are provided to their patients. Findings indicate that the majority of drug treatment programs educate at least some of their patients about HCV, and provide some type of support for patients who are infected with the virus. Only 29 of the programs in the sample test all of their patients for HCV, however, and 99 programs test none of them. For the most part, residential treatment programs offer more HCV related services than outpatient drug-free programs.

KW - Disease prevention

KW - Drug treatment programs

KW - HCV services

KW - Telephone survey

KW - Treatment modality

UR - http://www.scopus.com/inward/record.url?scp=0036202472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036202472&partnerID=8YFLogxK

U2 - 10.1016/S0740-5472(01)00213-6

DO - 10.1016/S0740-5472(01)00213-6

M3 - Article

C2 - 11932130

AN - SCOPUS:0036202472

SN - 0740-5472

VL - 22

SP - 55

EP - 62

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

IS - 2

ER -

A nationwide survey of hepatitis C services provided by drug treatment programs

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this